Durable response to nivolumab in combination with regional hyperthermia in a patient with PD-L1-negative metastatic head and neck squamous cell carcinoma

被引：0

作者：

Luc M. Berclaz ^{[1
]}

Anton Burkhard-Meier ^{[2
]}

Axel Lechner ^{[1
]}

Michael Völkl ^{[3
]}

Sinan E. Güler ^{[1
]}

Sultan Abdel-Rahman ^{[1
]}

Sina Mansoorian ^{[1
]}

Wolfgang G. Kunz ^{[4
]}

Thomas Knösel ^{[5
]}

Martin Canis ^{[6
]}

Michael von Bergwelt-Baildon ^{[3
]}

Rolf D. Issels ^{[1
]}

Dorit Di Gioia ^{[2
]}

Lars H. Lindner ^{[1
]}

机构：

[1] University Hospital,Department of Internal Medicine III

[2] LMU Munich,Deparment of Otorhinolaryngology

[3] German Cancer Consortium (DKTK),Department of Radiation Oncology

[4] Partner Site Munich,Department of Radiology

[5] University Hospital,Institute of Pathology

[6] LMU Munich,undefined

[7] University Hospital,undefined

[8] LMU Munich,undefined

[9] University Hospital,undefined

[10] LMU Munich,undefined

[11] LMU Munich,undefined

来源：

Cancer Immunology, Immunotherapy | / 74卷 / 6期

关键词：

Immunotherapy; Immune checkpoint inhibitors; Head and neck cancer; Regional hyperthermia;

D O I：

10.1007/s00262-025-04029-9

中图分类号：

学科分类号：

摘要：

We report a long-lasting response to the immune checkpoint inhibitor nivolumab in combination with regional hyperthermia (RHT) in a patient with recurrent metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) and negative programmed death ligand 1 (PD-L1) expression. Treatment was well tolerated with no local side effects. Tumor-related symptoms in the orbital and masticator area gradually decreased under treatment with nivolumab and RHT. Over the course of treatment, magnetic resonance imaging (MRI) showed a local tumor control in the heated tumor areas, while metastatic lesions developed in areas outside of the RHT field. This is the first case report demonstrating the feasibility and clinical potential of the addition of RHT in this patient collective with poor outcomes and low response rates to immune checkpoint inhibitors. RHT might be an additional tool to activate an immunogenic milieu responsive to immune checkpoint inhibitors.

引用

共 50 条

[21] Targeting PD-L1 sensitizes head and neck squamous cell carcinoma to cisplatin
Qiao, Peter
Lajud, Shayanne A.
Nagda, Danish A.
Tanaka, Nobuaki
Civantos, Alyssa
O'Malley, Bert W.
Li, Daqing
CANCER RESEARCH, 2014, 74 (19)
[22] Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma
Jacob H. Rasmussen
Giedrius Lelkaitis
Katrin Håkansson
Ivan R. Vogelius
Helle H. Johannesen
Barbara M. Fischer
Søren M. Bentzen
Lena Specht
Claus A. Kristensen
Christian von Buchwald
Irene Wessel
Jeppe Friborg
British Journal of Cancer, 2019, 120 : 1003 - 1006
[23] PD-L1 regulates cisplatin chemoresistance in head and neck squamous cell carcinoma
Ruffner, Randall S.
Ramsey, Andrew
O'Malley, Bert W.
Li, Daqing
CANCER RESEARCH, 2015, 75
[24] PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma
Mueller, T.
Braegelmann, J.
Dietrich, D.
Perner, S.
Kristiansen, G.
Bootz, F.
Brossart, P.
ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 103 - 103
[25] Significance of PD-L1 testing in Outcome of Head and Neck Squamous Cell Carcinoma
Bancu, A.
Preetha, C.
JOURNAL OF PATHOLOGY, 2021, 255 : S26 - S26
[26] Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma
Rasmussen, Jacob H.
Lelkaitis, Giedrius
Hakansson, Katrin
Vogelius, Ivan R.
Johannesen, Helle H.
Fischer, Barbara M.
Bentzen, Soren M.
Specht, Lena
Kristensen, Claus A.
von Buchwald, Christian
Wessel, Irene
Friborg, Jeppe
BRITISH JOURNAL OF CANCER, 2019, 120 (10) : 1003 - 1006
[27] PD-L1: a novel prognostic biomarker in head and neck squamous cell carcinoma
Mueller, Tim
Braun, Martin
Dietrich, Dimo
Aktekin, Seher
Hoeft, Simon
Kristiansen, Glen
Goeke, Friederike
Schroeck, Andreas
Braegelmann, Johannes
Held, Stefanie A. E.
Bootz, Friedrich
Brossart, Peter
ONCOTARGET, 2017, 8 (32) : 52889 - 52900
[28] Impact of antibiotics on PD-1 inhibition in recurrent/metastatic head and neck squamous cell carcinoma
Rabjerg, Helene Knap
Eriksen, Jesper Grau
Soby, Sebastian
ORAL ONCOLOGY, 2024, 158
[29] Alpelisib and Immunotherapy: A Promising Combination for Recurrent and Metastatic Squamous Cell Carcinoma of the Head and Neck
Suleiman, Riham
McGarrah, Patrick
Baral, Binav
Owen, Dawn
Aguilera, Jesus Vera
Halfdanarson, Thor R.
Price, Katharine A.
Bayne, Harry E. Fuentes
CANCER REPORTS, 2024, 7 (10)
[30] Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma
Torchio, Martina
Cattaneo, Laura
Milione, Massimo
Prinzi, Natalie
Corti, Francesca
Ungari, Marco
Anichini, Andrea
Mortarini, Roberta
Occhini, Antonio
Bertino, Giulia
Maurichi, Andrea
Coppa, Jorgelina
Di Bartolomeo, Maria
de Braud, Filippo Guglielmo
Pusceddu, Sara
FRONTIERS IN ONCOLOGY, 2021, 11

← 1 2 3 4 5 →